Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2008
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged 12 to 17 years) with migraine headaches
Epistemonikos ID: e33e556b3122524c410d277e7fa26f7112e27ce3
First added on: May 04, 2024